Target family: P2Y receptors (type: gpcr)
Target: P2Y<sub>2</sub> receptor

Ligand: UTPγS (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pEC50
Reference (Journal): Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate.
Published in: Br J Pharmacol

Ligand: UTP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pEC50
Reference (Journal): Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate.
Published in: Br J Pharmacol

Ligand: UTP (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pEC50
Reference (Journal): Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.
Published in: J Med Chem

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 4.300000190734863 pIC50
Reference (Journal): An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor.
Published in: Br J Pharmacol

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 4.300000190734863 pIC50
Reference (Journal): Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants.
Published in: Br J Pharmacol

Ligand: reactive blue-2 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants.
Published in: Br J Pharmacol

Ligand: PSB-416 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.659999847412109 pIC50
Reference (Journal): Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
Published in: J Med Chem

Ligand: PSB1114 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pEC50
Reference (Journal): Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety.
Published in: Bioorg Med Chem Lett

Ligand: PSB1114 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pEC50
Reference (Journal): Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.
Published in: J Med Chem

Ligand: PSB1114 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pEC50
Reference (Journal): Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
Published in: J Med Chem

Ligand: MRS2768 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pEC50
Reference (Journal): Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.
Published in: Bioorg Med Chem